Who is the CEO of Epizyme, Inc.?

Mr. Robert Bazemore is a business executive who currently serves as the CEO of Epizyme, Inc..

What is the Revenue Growth of Epizyme, Inc.?

Revenue growth data for Epizyme, Inc. is currently unavailable.

What is Epizyme, Inc. operating Margin?

Epizyme, Inc. operating margin is -606.35% which shows how much profit EPZM earns from each dollar of sales, after subtracting the direct costs tied to generating that revenue.

In which market sector does Epizyme, Inc. operate?

Epizyme, Inc. falls under the Healthcare sector which thrives across multiple industries. It stays competitive through its diverse product lineup, which spans computer hardware, tech gadgets, video streaming services, and cloud computing solutions.

What is Epizyme, Inc. revenue growth?

Revenue growth data for Epizyme, Inc. is currently unavailable.

Epizyme, Inc.

EPZM•NASDAQ

HealthcareBiotechnology

$1.47

$0.00(0.00%)

Epizyme, Inc. (EPZM) Stock Overview

Explore Epizyme, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Stats data is not available for EPZMStats details for EPZM are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Analyst Recommendations data is not available for EPZMAnalyst Recommendations details for EPZM are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. As of August 11, 2022, Epizyme, Inc. operates as a subsidiary of Ipsen Biopharmaceuticals, Inc..

CEO

Mr. Robert Bazemore

Employees

250

Headquarters

400 Technology Sq Ste 4, Cambridge, MASSACHUSETTS

Founded

2013